• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Weiner Daniel L was granted 786 shares, increasing direct ownership by 10% to 8,809 units (SEC Form 4)

    5/1/25 4:21:57 PM ET
    $SLP
    EDP Services
    Technology
    Get the next $SLP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WEINER DANIEL L

    (Last) (First) (Middle)
    800 PARK OFFICES DRIVE
    SUITE 401

    (Street)
    RESEARCH TRIANGLE PARK NC 27709

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Simulations Plus, Inc. [ SLP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/01/2025 A 786 A $0(1) 8,809 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Stock granted as independent director compensation, issued under the issuer's 2021 Equity Incentive Plan.
    Remarks:
    /s/ Daniel Hoeft, attorney-in-fact for Daniel L. Weiner 05/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SLP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLP

    DatePrice TargetRatingAnalyst
    11/15/2024$39.00Overweight
    Stephens
    7/29/2024$47.00Overweight
    KeyBanc Capital Markets
    7/16/2024Mkt Perform
    JMP Securities
    6/28/2024Outperform
    William Blair
    5/9/2023$55.00Buy
    BTIG Research
    10/26/2021$65.00 → $53.00Hold → Buy
    Craig Hallum
    7/13/2021$95.00 → $54.00Outperform
    Raymond James
    More analyst ratings

    $SLP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Simulations Plus Releases ADMET Predictor® 13

      Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13 features advancements in three main areas: First-to-invent advantage: clients can harness enhanced high-thr

      6/5/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Releases DILIsym® 11

      Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. "Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are essential to developing safer treatments," said Shawn O'Connor, Chief Executive Officer o

      5/15/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

      Modeling and simulation will be a key component for shift to non-animal methodologies Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i

      4/21/25 7:50:00 AM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Financials

    Live finance-specific insights

    See more
    • Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

      Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software revenue increased 16% to $13.5 million, repres

      4/3/25 4:05:00 PM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

      Conference call to be on Thursday, April 3, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse

      3/20/25 7:00:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

      Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro

      1/7/25 4:06:00 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    SEC Filings

    See more
    • Simulations Plus Inc. filed SEC Form 8-K: Leadership Update, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Simulations Plus, Inc. (0001023459) (Filer)

      6/2/25 7:55:20 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Simulations Plus, Inc. (0001023459) (Filer)

      4/18/25 8:34:07 AM ET
      $SLP
      EDP Services
      Technology
    • SEC Form 10-Q filed by Simulations Plus Inc.

      10-Q - Simulations Plus, Inc. (0001023459) (Filer)

      4/4/25 7:55:42 AM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Simulations Plus with a new price target

      Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00

      11/15/24 8:20:56 AM ET
      $SLP
      EDP Services
      Technology
    • KeyBanc Capital Markets initiated coverage on Simulations Plus with a new price target

      KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00

      7/29/24 7:43:47 AM ET
      $SLP
      EDP Services
      Technology
    • JMP Securities initiated coverage on Simulations Plus

      JMP Securities initiated coverage of Simulations Plus with a rating of Mkt Perform

      7/16/24 7:49:15 AM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Simulations Plus Inc.

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      8/8/24 2:18:03 PM ET
      $SLP
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      2/13/24 5:13:58 PM ET
      $SLP
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Simulations Plus Inc. (Amendment)

      SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)

      2/12/24 4:59:04 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woltosz Walter S sold $543,074 worth of shares (20,000 units at $27.15), decreasing direct ownership by 0.60% to 3,324,157 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      6/3/25 4:57:16 PM ET
      $SLP
      EDP Services
      Technology
    • Director Woltosz Walter S was granted 786 shares and sold $670,150 worth of shares (20,000 units at $33.51), decreasing direct ownership by 0.57% to 3,344,157 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      5/1/25 5:53:05 PM ET
      $SLP
      EDP Services
      Technology
    • Director Evans Sharlene was granted 786 shares, increasing direct ownership by 9% to 9,435 units (SEC Form 4)

      4 - Simulations Plus, Inc. (0001023459) (Issuer)

      5/1/25 4:27:34 PM ET
      $SLP
      EDP Services
      Technology

    $SLP
    Leadership Updates

    Live Leadership Updates

    See more
    • QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus

      QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi

      6/12/24 8:58:00 AM ET
      $SLP
      EDP Services
      Technology
    • Simulations Plus Names Industry Veteran Will Frederick as Chief Financial Officer

      LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among

      12/1/20 4:05:00 PM ET
      $DIS
      $SLP
      $F
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      EDP Services
      Technology